• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物组操纵对非酒精性脂肪性肝病患者血糖指数的影响:综合伞状评价。

The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review.

机构信息

Guilan University of Medical Sciences, Rasht, Iran.

Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.

出版信息

Nutr Diabetes. 2024 May 10;14(1):25. doi: 10.1038/s41387-024-00281-7.

DOI:10.1038/s41387-024-00281-7
PMID:38729941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11087547/
Abstract

BACKGROUND

Type 2 diabetes mellitus (T2DM) is a significant risk factor for non-alcoholic fatty liver disease (NAFLD). Increased fasting blood sugar (FBS), fasting insulin (FI), and insulin resistance (HOMA-IR) are observed in patients with NAFLD. Gut microbial modulation using prebiotics, probiotics, and synbiotics has shown promise in NAFLD treatment. This meta-umbrella study aimed to investigate the effects of gut microbial modulation on glycemic indices in patients with NAFLD and discuss potential mechanisms of action.

METHODS

A systematic search was conducted in PubMed, Web of Science, Scopus, and Cochrane Library until March 2023 for meta-analyses evaluating the effects of probiotics, prebiotics, and synbiotics on patients with NAFLD. Random-effect models, sensitivity analysis, and subgroup analysis were employed.

RESULTS

Gut microbial therapy significantly decreased HOMA-IR (ES: -0.41; 95%CI: -0.52, -0.31; P < 0.001) and FI (ES: -0.59; 95%CI: -0.77, -0.41; P < 0.001). However, no significant effect was observed on FBS (ES: -0.17; 95%CI: -0.36, 0.02; P = 0.082). Subgroup analysis revealed prebiotics had the most potent effect on HOMA-IR, followed by probiotics and synbiotics. For FI, synbiotics had the most substantial effect, followed by prebiotics and probiotics.

CONCLUSION

Probiotics, prebiotics, and synbiotics administration significantly reduced FI and HOMA-IR, but no significant effect was observed on FBS.

摘要

背景

2 型糖尿病(T2DM)是非酒精性脂肪性肝病(NAFLD)的重要危险因素。NAFLD 患者存在空腹血糖(FBS)、空腹胰岛素(FI)和胰岛素抵抗(HOMA-IR)升高的情况。使用益生元、益生菌和合生元调节肠道微生物已显示出在 NAFLD 治疗中的潜力。本元分析旨在研究肠道微生物调节对 NAFLD 患者血糖指标的影响,并探讨其潜在的作用机制。

方法

对 PubMed、Web of Science、Scopus 和 Cochrane Library 进行系统检索,以评估益生菌、益生元和合生元对 NAFLD 患者影响的元分析,检索时间截至 2023 年 3 月。采用随机效应模型、敏感性分析和亚组分析。

结果

肠道微生物治疗显著降低了 HOMA-IR(ES:-0.41;95%CI:-0.52,-0.31;P<0.001)和 FI(ES:-0.59;95%CI:-0.77,-0.41;P<0.001)。然而,FBS 没有观察到显著的影响(ES:-0.17;95%CI:-0.36,0.02;P=0.082)。亚组分析表明,在 HOMA-IR 方面,益生元的作用最强,其次是益生菌和合生元;在 FI 方面,合生元的作用最显著,其次是益生元和益生菌。

结论

益生菌、益生元和合生元的应用显著降低了 FI 和 HOMA-IR,但对 FBS 没有显著影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/ada173d040b5/41387_2024_281_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/0cfa93b6e6f7/41387_2024_281_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/46ffe8f08897/41387_2024_281_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/400ca806e960/41387_2024_281_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/8bc6a8150ed5/41387_2024_281_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/ada173d040b5/41387_2024_281_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/0cfa93b6e6f7/41387_2024_281_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/46ffe8f08897/41387_2024_281_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/400ca806e960/41387_2024_281_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/8bc6a8150ed5/41387_2024_281_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f64/11087547/ada173d040b5/41387_2024_281_Fig5_HTML.jpg

相似文献

1
The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review.肠道微生物组操纵对非酒精性脂肪性肝病患者血糖指数的影响:综合伞状评价。
Nutr Diabetes. 2024 May 10;14(1):25. doi: 10.1038/s41387-024-00281-7.
2
The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis.肠道微生物组靶向治疗对非酒精性脂肪性肝病患者肝酶的影响:伞式荟萃分析。
Nutr Rev. 2024 May 10;82(6):815-830. doi: 10.1093/nutrit/nuad086.
3
Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses.益生菌和合生菌对非酒精性脂肪性肝病患者的抗炎作用:荟萃分析的伞状研究。
Clin Nutr ESPEN. 2023 Oct;57:475-486. doi: 10.1016/j.clnesp.2023.07.087. Epub 2023 Jul 31.
4
Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study.肠道微生物治疗对非酒精性脂肪性肝病患者血脂谱的影响:伞式荟萃分析研究。
Syst Rev. 2023 Aug 21;12(1):144. doi: 10.1186/s13643-023-02299-x.
5
Meta-analysis of randomized controlled trials of the effects of synbiotics, probiotics, or prebiotics in controlling glucose homeostasis in non-alcoholic fatty liver disease patients.益生菌、益生元和合生元治疗非酒精性脂肪性肝病患者糖代谢紊乱的随机对照试验的荟萃分析。
Food Funct. 2024 Sep 30;15(19):9954-9971. doi: 10.1039/d4fo02561j.
6
Gut microbiota interventions in type 2 diabetes mellitus: An umbrella review of glycemic indices.肠道微生物群干预 2 型糖尿病:血糖指数的伞式综述。
Diabetes Metab Syndr. 2024 Aug;18(8):103110. doi: 10.1016/j.dsx.2024.103110. Epub 2024 Aug 23.
7
The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis.益生菌、益生元或合生菌对糖尿病患者代谢结局的影响:系统评价和荟萃分析。
Diabetologia. 2021 Jan;64(1):26-41. doi: 10.1007/s00125-020-05295-1. Epub 2020 Oct 13.
8
Can modulation of gut microbiota affect anthropometric indices in patients with non-alcoholic fatty liver disease? An umbrella meta-analysis of randomized controlled trials.肠道微生物群的调节能否影响非酒精性脂肪性肝病患者的人体测量指标?一项随机对照试验的伞状荟萃分析。
Ann Med Surg (Lond). 2024 Jan 25;86(5):2900-2910. doi: 10.1097/MS9.0000000000001740. eCollection 2024 May.
9
GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN MANAGEMENT OF OBESITY AND PREDIABETES: REVIEW OF RANDOMIZED CONTROLLED TRIALS.肠道微生物群、益生元、益生菌和合生菌在肥胖和糖尿病管理中的应用:随机对照试验综述。
Endocr Pract. 2016 Oct;22(10):1224-1234. doi: 10.4158/EP151157.RA. Epub 2016 Jul 13.
10
Probiotics, prebiotics, synbiotics and insulin sensitivity.益生菌、益生元、合生菌与胰岛素敏感性。
Nutr Res Rev. 2018 Jun;31(1):35-51. doi: 10.1017/S095442241700018X. Epub 2017 Oct 17.

引用本文的文献

1
The gut-retina axis: association of dietary index for gut microbiota with diabetic retinopathy in diabetic patients-a cross-sectional study from NHANES 2009-2018.肠道-视网膜轴:糖尿病患者肠道微生物群饮食指数与糖尿病视网膜病变的关联——一项基于2009 - 2018年美国国家健康与营养检查调查(NHANES)的横断面研究
Diabetol Metab Syndr. 2025 Aug 27;17(1):359. doi: 10.1186/s13098-025-01929-9.
2
The impact of weight loss interventions on thyroid function: a systematic review and meta-analysis.体重减轻干预对甲状腺功能的影响:一项系统评价和荟萃分析。
Ann Med Surg (Lond). 2025 May 26;87(7):4484-4497. doi: 10.1097/MS9.0000000000003428. eCollection 2025 Jul.
3

本文引用的文献

1
The Value of Microbiome-targeted Therapy on Lipid Indices of Patients with Type 2 Diabetes Mellitus: An Umbrella Meta-analysis of Randomized Controlled Trials.靶向肠道菌群治疗对 2 型糖尿病患者血脂指标的影响:一项随机对照试验的伞状荟萃分析。
Curr Diabetes Rev. 2024;21(1):e180124225761. doi: 10.2174/0115733998284844240102110559.
2
The Prevalence of Non-Alcoholic Fatty Liver Disease in Iranian Children and Adult Population: A Systematic Review and Meta-Analysis.伊朗儿童和成人非酒精性脂肪性肝病的患病率:一项系统评价和荟萃分析
Iran J Public Health. 2023 Aug;52(8):1600-1612. doi: 10.18502/ijph.v52i8.13399.
3
Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses.
Prevalence of nonalcoholic fatty liver disease in rheumatoid arthritis: An updated systematic review and meta-analysis.
类风湿关节炎中非酒精性脂肪性肝病的患病率:一项更新的系统评价和荟萃分析。
Medicine (Baltimore). 2025 Aug 8;104(32):e43641. doi: 10.1097/MD.0000000000043641.
4
Association between attention-deficit/hyperactivity disorders and intestinal disorders: A systematic review and Meta-analysis.注意力缺陷/多动障碍与肠道疾病之间的关联:一项系统综述和Meta分析。
Sci Rep. 2025 Jun 2;15(1):19278. doi: 10.1038/s41598-025-04303-x.
5
The association between new insulin resistance indices and all-cause mortality in elderly patients with diabetes: a prospective cohort study.老年糖尿病患者新胰岛素抵抗指数与全因死亡率的关联:一项前瞻性队列研究。
Diabetol Metab Syndr. 2025 May 30;17(1):181. doi: 10.1186/s13098-025-01732-6.
6
Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.合生制剂对非酒精性脂肪肝患者心血管危险因素的影响:一项GRADE评估的系统评价和荟萃分析。
BMC Gastroenterol. 2025 May 26;25(1):407. doi: 10.1186/s12876-025-03789-z.
7
Neutrophil Percentage-to-Albumin Ratio and Neutrophil-to-Albumin Ratio as novel biomarkers for non-alcoholic fatty liver disease: a systematic review and meta-analysis.中性粒细胞百分比与白蛋白比值及中性粒细胞与白蛋白比值作为非酒精性脂肪性肝病的新型生物标志物:一项系统评价和荟萃分析
J Health Popul Nutr. 2025 May 24;44(1):167. doi: 10.1186/s41043-025-00926-y.
8
Triglyceride glucose waist circumference and non alcoholic fatty liver disease: a systematic review and meta analysis.甘油三酯、血糖、腰围与非酒精性脂肪性肝病:一项系统评价与荟萃分析
BMC Gastroenterol. 2025 May 1;25(1):328. doi: 10.1186/s12876-025-03888-x.
9
Exploring causal correlations between immune cells and diabetic neuropathy: a Mendelian randomization.探索免疫细胞与糖尿病性神经病变之间的因果关系:孟德尔随机化研究
Diabetol Metab Syndr. 2025 Apr 15;17(1):127. doi: 10.1186/s13098-025-01696-7.
10
Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis.二肽基肽酶-4抑制剂与心血管结局的全球研究趋势:一项全面的文献计量分析
Ann Med Surg (Lond). 2025 Mar 27;87(4):2133-2148. doi: 10.1097/MS9.0000000000003089. eCollection 2025 Apr.
益生菌和合生菌对非酒精性脂肪性肝病患者的抗炎作用:荟萃分析的伞状研究。
Clin Nutr ESPEN. 2023 Oct;57:475-486. doi: 10.1016/j.clnesp.2023.07.087. Epub 2023 Jul 31.
4
Association between the Triglyceride-Glucose Index and Non-Alcoholic Fatty Liver Disease in patients with Atrial Fibrillation.甘油三酯-葡萄糖指数与房颤患者非酒精性脂肪肝的相关性。
Eur J Med Res. 2023 Sep 19;28(1):355. doi: 10.1186/s40001-023-01188-2.
5
Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study.肠道微生物治疗对非酒精性脂肪性肝病患者血脂谱的影响:伞式荟萃分析研究。
Syst Rev. 2023 Aug 21;12(1):144. doi: 10.1186/s13643-023-02299-x.
6
The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis.肠道微生物组靶向治疗对非酒精性脂肪性肝病患者肝酶的影响:伞式荟萃分析。
Nutr Rev. 2024 May 10;82(6):815-830. doi: 10.1093/nutrit/nuad086.
7
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
8
Probiotic Mechanisms Affecting Glucose Homeostasis: A Scoping Review.影响葡萄糖稳态的益生菌机制:一项范围综述。
Life (Basel). 2022 Aug 3;12(8):1187. doi: 10.3390/life12081187.
9
The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis.益生菌/益生元/合生菌在非酒精性脂肪性肝病患者能量代谢生物标志物中的潜在作用:系统评价和荟萃分析。
Front Public Health. 2022 Jul 25;10:862266. doi: 10.3389/fpubh.2022.862266. eCollection 2022.
10
How do intestinal probiotics restore the intestinal barrier?肠道益生菌如何恢复肠道屏障?
Front Microbiol. 2022 Jul 14;13:929346. doi: 10.3389/fmicb.2022.929346. eCollection 2022.